WebMar 29, 2024 · On March 29, 2024, QED Therapeutics, Inc. (“QED”), a subsidiary of BridgeBio Pharma, Inc. (the “Company”), entered into a license and collaboration agreement (the “License and Collaboration Agreement”) with Helsinn Healthcare S.A. (“HHC”) and Helsinn Therapeutics (U.S.), Inc. (“HTU”, collectively with HHC, “Helsinn,” … WebMar 9, 2024 · Primecap Management Co. CA owned 0.69% of BridgeBio Pharma worth $10,315,000 as of its most recent SEC filing. Several other institutional investors and hedge funds have also modified their holdings of the stock. Itau Unibanco Holding S.A. acquired a new position in shares of BridgeBio Pharma in the third quarter worth about $28,000. …
SVB Securities Maintains BridgeBio Pharma (BBIO) Outperform
WebMay 12, 2024 · - BridgeBio is eligible to receive up to $905 million, including an upfront payment of $90 million, and up to $815 million in additional milestone payments and royalties WebMar 29, 2024 · of the Securities Exchange Act of 1934 ... (Date of earliest event reported): March 29, 2024 . BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) Delaware : 001-38959 : 84-1850815 ... Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant ... morrowind brallion
BridgeBio Pharma Announces Proposed Public Offering of …
Web-Ended quarter with $840.9 million in cash, cash equivalents and marketable securities SAN FRANCISCO, AUGUST 11, 2024 – BridgeBio Pharma, Inc. (Nasdaq: BBIO), a … WebApr 11, 2024 · SEC filings and transcripts for BridgeBio Pharma Inc, including financials, news, proxies, indentures, prospectuses, and credit agreements BridgeBio Pharma Inc … Web11 rows · Apr 7, 2024 · SEC Filings Group 3,4,5 Annual Filings Current Reports Mergers & Acquisitions Other Proxy Filings Quarterly Filings Registration Statements Filing year - Any - 2024 2024 2024 2024 2024 2024 morrowind box